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Abstract
Purpose: Although exercise medicine is recommended to counter treatment-related side-effects and improve healthrelated outcomes of patients affected by different cancers, no specific recommendations exist for patients with melanoma.
As a result, we systematically examined the current evidence regarding the effects of physical activity and exercise on
objectively-measured and patient-reported outcomes among patients with melanoma. Methods: Searches were conducted
in PubMed, CINAHL, EMBASE, SPORTDiscus, and Web of Science databases. This review included published data involving
physical activity or exercise and objectively-measured or patient-reported outcomes of patients with cutaneous melanoma.
The quality of included studies was assessed using the McMaster University Critical Appraisal Tool for Quantitative
Studies. Results: Six studies including 882 patients with melanoma were included. Studies presented heterogeneity of
design with 2 cross-sectional surveys, 2 retrospective analyses, and 2 non-randomized intervention trials. No statistically
significant change in quality of life, fatigue, physical function, cardiorespiratory fitness, body composition, psychological
distress, cognitive function, or treatment-related side-effects were attributable to physical activity or exercise. Importantly,
physical activity or exercise during melanoma treatment or into survivorship did not adversely impact patients/survivors.
Conclusion: In summary, physical activity or exercise did not adversely impact quality of life, objectively-measured or
patient-reported outcomes in patients with melanoma. In addition, there is a paucity of quality studies examining the
effects of physical activity or exercise on patients with melanoma throughout the cancer care continuum.
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Introduction
The worldwide incidence of melanoma has increased over
the past few decades and in 2020 approximately 325 000
new cases and more than 57 000 deaths were observed.1 In
Australia, cutaneous melanoma is the second and third
most commonly diagnosed cancer among men and women,
respectively.2 Moreover, despite a lower incidence globally compared to other solid tumors, melanoma has a high
incidence among adolescents and younger adults.1 Most
patients with melanoma are treated with surgery alone,
whereas radiotherapy, and systemic treatment with targeted or immunotherapy, are utilized for patients with
more advanced disease.3

Novel systemic therapies such as targeted therapy with
BRAF inhibitors and immune checkpoint inhibitors have
demonstrated a survival advantage in patients with advanced
melanoma.4,5 However, these treatments are not without
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risk and adverse effects; dermatological, gastrointestinal,
hepatic, and endocrine toxicities are frequently experienced
by patients.5-7 Immune-related adverse events (irAEs)
resulting from treatment with immune checkpoint inhibitors
are distinctly different from the classical chemotherapyrelated toxicities. However, several symptoms such as
fatigue and weakness, diarrhea, arthralgia, and reductions in
muscle mass are common, substantially affecting quality of
life (QoL) and wellbeing of the patients during and potentially following the completion of treatment.6,8,9
Furthermore, patients with cancer also experience substantial reductions in muscle mass (ie, sarcopenia) as a result of
aging and physical inactivity and this has been shown to be
associated with poorer cancer treatment outcomes.8
Physical activity (eg, any bodily movement produced by
skeletal muscles) and exercise (eg, physical activity that is
planned, structured, repetitive, and purposive) have been
suggested to mitigate and counteract primary treatment sideeffects10; and have been endorsed by many professional
organizations such as the American College of Sports
Medicine,11-14 American Cancer Society,15,16 Spanish Society
of Medical Oncology,17 and Exercise and Sports Science
Australia.18,19 Existing guidelines cover exercise recommendations for various types of cancer (eg, lung, prostate, breast,
lymphoma) and treatment phases (pre-treatment, treatment,
survivorship, and palliation). However, a substantial gap
exists for patients with melanoma. For example, it remains
unclear if exercising pre- or post- melanoma diagnosis is
associated with any survival benefit,20 although it has been
shown that these patients are presenting with significant
reductions in physical activity levels post treatment.21 The
reduction in physical activity, especially in older adults,
could increase the risk of sarcopenia as well as cardiovascular and metabolic diseases.22,23 As commonly observed in
the aforementioned cancers, it may be that among patients
with melanoma, exercise promotes significant benefits by
reducing treatment-related side-effects and enhancing QoL
through the course of treatment and beyond.
Given the paucity of information regarding physical
activity and exercise in patients with melanoma, the present
study aims to systematically review and examine the effects
of physical activity and exercise on QoL as the primary outcome, and other objectively-measured (body composition,
cardiorespiratory fitness, and physical function), and
patient-reported (fatigue, treatment-related side-effects,
cognitive function, and psychological distress) outcomes
among patients with melanoma.

Methods
Study Selection Procedure
The study was undertaken in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
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(PRISMA) statement,24,25 and the method used was based
on the minimum criteria established by the Cochrane Back
Review Group (CBRG).26 This systematic review was not
registered in any prospectively systematic review database
(eg, PROSPERO).
This review included studies reporting on the impact of
physical activity or exercise interventions on quality of
life, or other objectively-measured and patient-reported
outcomes in adult patients with cutaneous melanoma. The
primary aim of this review was to examine the relationship
between physical activity or exercise and QoL. The secondary aims were to evaluate the relationship between
physical activity or exercise and other objectively-measured (body composition, and physical function) and
patient-reported (fatigue, treatment-related side-effects,
cognitive function, and psychological distress) outcomes.
Studies were excluded if: (1) they involved mixed cancer
patients without specific information on results from
patients with melanoma; (2) they did not include or report
the specific outcomes included in this review; (3) they
involved pediatric patients with melanoma, and (4) were
written in a language other than English. Eligibility was
assessed and independently evaluated in duplicate, with
differences resolved by consensus between the 2 reviewers
(BC and PL), and in case of disagreement, a third reviewer
(FS) was consulted.
The search was conducted up to February 2021 using the
following electronic databases: PubMed, CINAHL,
EMBASE, SPORTDiscus, and Web of Science. The terms
used were: “Melanoma,” “Physical Activity,” and
“Exercise” in association with a list of sensitive terms to
search for experimental studies. We also performed a manual search of the reference lists provided in the selected
papers. In addition, 2 melanoma-specific systematic
reviews27,28 that did not specifically focus on patient outcomes were assessed to detect studies potentially eligible
for inclusion. The search strategy used is presented in the
Supplemental Digital Content Appendix 1.

Data Extraction
Titles and abstracts of all articles identified through the
search strategy were independently evaluated by 2 reviewers (BC and PL). Abstracts that did not provide sufficient
information regarding the inclusion criteria were selected
for full-text evaluation. In the second phase, the same 2
reviewers independently evaluated these full-text articles
and selected them in accordance with the eligibility criteria.
Disagreements between reviewers were resolved by consensus, with a third reviewer (FS) consulted when necessary. The data extraction was performed via a standardized
form. Descriptive characteristics such as cancer type, participant and treatment characteristics, and study outcomes
were collected.
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Quality Assessment
The quality of all included studies was assessed using the
McMaster University Critical Appraisal Tool for
Quantitative Studies.29 This tool includes 16 questions and
covers the following components: study purpose (Was the
purpose clearly stated?), literature (Was relevant background literature reviewed?), design (Is the study design
appropriate to study aims?, No biases present?), sample
(Was the sample described in detail?, Was sample size justified?), outcomes (Were the outcome measures reliable?,
Were the outcome measures valid?), intervention
(Intervention was described in detail?, Contamination was
avoided?, Co-intervention was avoided?), results (Results
were reported in terms of statistical significance?, Were the
analysis method(s) appropriate?, Clinical importance was
reported?, Drop-outs were reported?), and conclusion and
implications (Conclusions were appropriate given study
methods and results). Each question was rated and scored as
1 for yes, 0 for no, and NA for not applicable based on each
study. A sum score was calculated for each study with
higher scores indicating higher methodological quality. The
risk of bias assessment for all included studies was performed independently by 2 reviewers (BC and PL). Any
disagreements between reviewers were resolved by consensus through discussion with a third reviewer (FS).

Data Synthesis
A narrative/qualitative synthesis was the preferred method
to provide an overview of the current literature on the topic.
Given the limited number of eligible trials, heterogeneity of
study designs, outcomes, and measurement tools, a metaanalysis was not undertaken. Information extracted from
studies included participant demographics, health history,
melanoma stage, treatment type, exercise behavior/physical
activity levels, and exercise intervention information (frequency, intensity, time, type), as well as information on
quality of life, fatigue, body composition/weight, physical
function, treatment-related side-effects, psychological distress, cognitive function, and lymphoedema. When available, descriptive data as mean, median, and dispersion
values (eg, standard deviation, 95% confidence intervals
[95% CI]) from studies were reported.

Results
Study Selection
Of the 1745 retrieved studies based on the search strategy,
1209 were retained for screening after duplicate removals.
Upon evaluation of titles and abstracts, 1157 articles were
excluded due to their irrelevance for the research question
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and the remaining 52 articles were retrieved in full text for
further examination. After a comprehensive assessment, 5
articles30-34 met the criteria to be included in this systematic
review. In addition, 1 study35 met the inclusion criteria and
was included based on the manual search. Detailed information regarding the process of study selection is shown in
Figure 1.

Study Characteristics
A total of 882 patients with melanoma, aged 20 to 85 years,
participated in the 6 included studies.30-35 There was considerable heterogeneity regarding cancer characteristics and
timing of assessment, with cancer staging ranging from
stage II to IV. In addition, the timing of study assessment
was during treatment,32-34 post-treatment,32,35 and 1 to
10 years following diagnosis30,31 (Table 1). A variety of
treatments were reported including surgery (3 of 6,
50%),30,31,35 immunotherapy (2 of 6, 33.3%),32,33 and interferon-alpha (IFN-α) (1 of 6, 16.6%).34 Of the 6 studies
included in this review, 2 were cross-sectional surveys,30,32
2 were retrospective analyses,31,35 and 2 were non-randomized intervention trials.33,34. Regarding the primary outcome
of this review, 3 studies included QoL assessment
(50%),30,31,33 while the remaining assessed treatment-related
side-effects (eg, lymphoedema) (3 of 6, 50%)31,33,35 fatigue
(3 of 6, 50%),32-34 body composition (2 of 6, 33.3%),33,34
physical function (2 of 6, 33.3%),33,34 psychological distress
(1 of 6, 16.6%),33 and cognitive function (1 of 6, 16.6%).34

Quality Assessment
The quality assessment is presented in Table 2. The overall
score ranged from 8 to 13 of a total of 16 points (ranging
from 50% to 81%). All studies30-35 met the criteria related to
purpose, relevant background, appropriate study design,
sample description, valid outcome measures, appropriate
analysis methods, and clinical importance. However, issues
related to design biases and sample size justification were
present in all studies. In addition, 3 studies31,33,35 (50%) did
not report the intervention in detail, or avoid intervention
contamination or co-intervention. Two studies31,35 did not
achieve the criteria in the reliability of the outcomes measure (33.3%), and 1 study did not report the results in terms
of statistical significance33 (16.7%), while another did not
provide a conclusion supported by the study methods and
results.35 Finally, 4 criteria were deemed “not applicable” in
2 of the studies due to study design. Controlling for intervention contamination, co-intervention, and describing the
intervention in detail were deemed not applicable in 2 studies30,32 (33%) while reporting results in terms of statistical
significance was not applicable in 1 study32 (16.7%).

4
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Figure 1. Flow chart of studies included.

Physical Activity Measures and Exercise
Prescription
Among the included studies, both physical activity behavior and physical activity/exercise interventions were
explored. In the cross-sectional studies of Blanchard et al30
and Hyatt et al,32 physical activity behavior was assessed by
undertaking surveys about weekly physical activities (eg,
aerobic or resistance training)32 or using the Godin LeisureTime Exercise Questionnaire.30 Patients were categorized
as physically active if they met the recommendations at the
time from the American Cancer Society (ie, completing
≥150 minutes of moderate-to-strenuous or 60 minutes of
strenuous physical activity per week)30 or Clinical Oncology
Society Australia exercise guidelines (ie, 150 minutes of
moderate-intensity or 75 minutes of vigorous-intensity

aerobic exercise and 2 to 3 resistance exercise sessions each
week).32 In the study by Schwartz et al,34 2 groups of
patients with melanoma (one group receiving IFN-α and
another composed of patients who had withdrawn from
IFN-α treatment within 1 week of commencement) were
instructed to follow a self-guided aerobic exercise program
with sessions of 15 to 30 minutes, 4 times a week for a duration of 4 months. However, given the relevance of IFN-α
treatment for current clinical practice (ie, no longer recommended for patients with melanoma), only the exercise
group not on IFN-α treatment34 was considered for further
analyses in this review. In the remaining 3 studies,31,33,35
exercise programs were delivered as follows: (1) 60 minute
sessions, 5 to 7 days (over 1-4 weeks) of multimodal therapy involving exercise with bandages,31,35 followed by 2 to
3 days per week of 10-minutes self-practice physical
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28

Lacey et al33

Interventional
study
57

Post-surgery (multimodal
therapy)

67% = 20 mg sustainedrelease methylphenidate,
33% not recorded

Treatment type

Stage IV

16% stage III,
84% stage IV

1-4 y postdiagnosis

2, 5 and
10 y post
diagnosis

Post groin
surgery

During
treatment

Timing
F- 4 sessions p/w for 4 mo
I- intensity limited by symptoms
T- 15-30 min per session
T- Aerobic exercise
F- 2-7 d p/w
I- NR
T- 10-60 min
T- bandage exercises/self-practice
physical activity
Classed as physically active if
>150 min of moderate or
>60 min of strenuous physical
activity p/w

Behavior/intervention

F- 2-7 d p/w
I- NR
T- 10-60 min
T- bandage exercises/self-practice
physical activity
During or post Classed as physically active if
78% currently receiving
treatment
>150 min of moderate or
immunotherapy (72%
>75 min of strenuous aerobic
single-agent, 26%
activity p/w + 2-3 resistance
combination, 2% unknown
exercise sessions p/w
During
F- 2 sessions p/w for 8-wk
Pembrolizumab 2 mg/kg
treatment
delivered at 3-weekly
I- NR
intervals
T- NR
T- Aerobic, resistance, qi gong,
yoga, or a combination

93.4% Localized, 95.9% surgery, 15.8%
5.5% Regional, chemotherapy, 9.5%
radiation therapy, 6.4%
1.1% Distant
hormone therapy, 6.8%
IFN-α/ IL-2, 11.3% bone
marrow transplant
Stage I-III
Post-surgery (multimodal
therapy)

NR

16% stage II,
84% stage III

Disease stage

FACT-G
FACT-G
Modified balke treadmill test, 1RM
strength (leg press, seated row)
NR
ESAS, HADS

PROMIS SF7a.
Open ended questions.

IDI-ILA part II
Limb circumference

#

Results
↔ Fatigue
↔ Functional ability
↔ Body composition
↔ Cognitive function
↑ (60%) limb volumes#

↔ QoL#
↔ Fatigue
↔ Physical function
↔ Body composition
↔ Patient-reported outcomes

↔ Fatigue#
↔ Self-reported perspectives

↑ (NR) QoL#
↑ (22%) limb volumes

RAND-36 health status inventory ↑ QoL#
score

Schwartz cancer fatigue scale
12-min walk test
NR
Trail maker form A and B
Limb circumference

Assessment tool/s

Abbreviations: *, Only 4 participants no longer receiving IFN-α were considered for further analyses; #, primary outcome of interest; ↔, no statistically significant change; ↑, statistically significant improvement; ↓, statistically
significant deterioration; NR, not reported; FITT, frequency, intensity, time, type; IDI-ILA part II, Istituto Dermopatico Dell’immacolata Italian Lymphedema Association questionnaire part II; PROMIS SF7a, Patient-reported
outcomes measurement information system fatigue–short form 7a; FACT-G, functional assessment of cancer therapy general; 1RM, one repetition maximum; ESAS, edmonton symptom assessment scale; HADS, hospital anxiety
and depression scale.

66 y (42-85 y)

36

55

Hyatt et al32

Crosssectional
survey

54.0 ± 10.0 y

12

Carmeli and
Bartoletti31

Retrospective
analysis

33

50

761 60.2 ± 13.4 y

Blanchard
et al30

Crosssectional
survey

58 ± 7.4 y

21

53 y (38-84 y)

14

Hinrichs
et al35

NR

% of males

Retrospective
analysis

Age

12* 44 y (20-64 y)

N

Schwartz
et al34

Study

Interventional
study

Design

Table 1. Descriptive Study Data.
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Table 2. Assessment of Study Quality Using the McMaster University Critical Appraisal Tool for Quantitative Studies.

Study purpose
Was the purpose clearly stated?
Literature
Was relevant background literature reviewed?
Design
Is the study design appropriate to study aims?
No biases present?
Sample
Was the sample described in detail?
Was sample size justified?
Outcomes
Were the outcome measures reliable?
Were the outcome measures valid?
Intervention
Intervention was described in detail?
Contamination was avoided?
Co-intervention was avoided?
Results
Results were reported in terms of statistical significance?
Were the analysis method(s) appropriate?
Clinical importance was reported?
Drop-outs were reported?
Conclusion and implications
Conclusions were appropriate given study methods and results
Total

Schwartz
et al34

Hinrichs
et al35

Blanchard
et al30

Carmeli and
Bartoletti31

Hyatt
et al32

Lacey
et al33

1

1

1

1

1

1

1

1

1

1

1

1

1
0

1
0

1
0

1
0

1
0

1
0

1
0

1
0

1
0

1
0

1
0

1
0

1
1

0
1

1
1

0
1

1
1

1
1

1
1
1

0
0
0

NA
NA
NA

0
0
0

NA
NA
NA

0
0
0

1
1
1
0

1
1
1
0

1
1
1
0

1
1
1
0

NA
1
1
0

0
1
1
1

1
13/16

0
8/16

1
10/13

1
9/16

1
9/12

1
10/16

Abbreviation: NA, not applicable.

activity until return of the limb to normal size, and (2)
8 weeks of multimodal supportive care intervention using
any combination of aerobic, resistance, qi gong, and yoga
exercises twice per week.33 No further information regarding physical activity or exercise components were reported.

physical activity and increased QoL (P < .05) in both localized and regional melanoma survivors. However, changes
in QoL were not observed in patients with regional and
metastatic melanoma following 8 weeks of multimodal supportive care in the study by Lacey et al.33

Outcomes

Fatigue. Fatigue was assessed using the FACT-G33 and the
Schwartz Cancer Fatigue Scale34 in the intervention studies, while one cross-sectional study32 assessed fatigue with
the Patient-Reported Outcomes Measurement Information
System Fatigue–Short Form 7a (PROMIS SF7a) and
recorded participants’ perspectives with open-ended questions. Hyatt et al32 reported that among patients with melanoma with regional and metastatic disease, fatigue scores
were slightly higher (54.8 ± 9.0) on the PROMIS SF7a
than the standardized mean of 50. Additionally, in openended questions from the survey, multiple participants
attributed experiencing fewer fatigue symptoms during
treatment to their physical activity/exercise. Comparatively, no difference was observed between the intervention and control group in the study of Lacey et al33
(39.7 ± 8.4 to 40.4 ± 8.8 in the intervention group;
42.8 ± 7.0 to 43.8 ± 8.8 in the control group) or in the

Quality of life. Three studies reported on QoL using different
questionnaires including the RAND-36 Health Status
Inventory Score,30 Istituto Dermopatico Dell’immacolata
Italian Lymphedema Association questionnaire part II,31
and the Functional Assessment of Cancer Therapy General
(FACT-G).33 Based on these reports, localized (stage I and/
or II), regional (stage III), and metastatic (stage IV) melanoma survivors in the survey study of Blanchard et al30
meeting the recommendations36 for a healthy lifestyle (ie,
physical activity, fruit and vegetable consumption, and nonsmoking) reported higher QoL compared to those not following the recommendation (53.7 ± 8.9 vs 50.6 ± 9.5;
P < .001). Similar results were observed in the retrospective study of Carmeli and Bartoletti,31 reporting a statistically significant association between higher levels of
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study of Schwartz et al34 (11-18 pts in the intervention
group), although the effect of exercise was above the minimum clinically important difference of 5 points.37
Body composition and body weight. Lacey et al33 reported
no change in body fat percentage (from 32.0% ± 11.5%
to 32.6% ± 11.3%), and a reduction in fat-free mass
(from 56.7 ± 19.7 kg to 54.1 ± 18.6 kg) after undertaking a tailored multimodal 8-week supportive care intervention, although the assessment method was not
reported. Both intervention studies33,34 indicated a
change in body weight; however, neither reported
within-group statistical significance. Lacey et al33
observed a reduction in body weight of 1 kg over
8 weeks, while Schwartz et al34 reported a reduction of
8.2 kg (85 ± 17.8 kg to 76.8 ± 17.7 kg) after the 4-month
self-guided exercise intervention.
Physical function. Both intervention studies33,34 evaluated
physical function before and after the intervention programs. In addition, Lacey et al33 reported upper and lower
body muscle strength pre-and post-training of
32.1 ± 9.4 kg and 37.9 ± 12.3 kg for seated row and
67.1 ± 17.2 kg and 57.9 ± 19.7 kg for leg press, although
no statistical comparison was undertaken. To assess cardiorespiratory capacity (cardiovascular fitness), Lacey
et al33 utilized a modified Balke treadmill test with determination of peak oxygen uptake (VO2 peak) and described
the results for the intervention group as stable (from
56 ± 30 ml.kg.min−1 to 51 ± 34 ml.kg.min−1) throughout
the study. Schwartz et al34 evaluated aerobic capacity
with a 12-minute walk test and concluded that on average
participants improved by 6% over the 4-month exercise
intervention period.
Treatment-related side-effects, psychological distress, cognitive function, and lymphoedema. Lacey et al33 examined
treatment-related side-effects and psychological distress
in patients with melanoma with regional and metastatic
disease during treatment. No changes were observed after
the intervention regarding the Edmonton Symptom
Assessment Scale (ESAS) and Hospital Anxiety and
Depression Scale (HADS) over 8 weeks of study duration. Schwartz et al34 reported cognitive function scores
relative to the Trail Maker Form A and B. Over the
4-month study duration, a reduction of 5 seconds for Form
A and 10 seconds for Form B was observed in exercising
patients with melanoma.34 A significant reduction in postsurgery lymphoedema was observed in the retrospective
studies of Carmeli & Bartoletti31 and Hinrichs et al.35 In
both studies, patients who undertook the multimodal
intervention presented significant reductions in lymphoedema assessed by limb volume (average reduction of
41%, ranging from −6035 to −22%31).
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Discussion
In this review, we examined the effectiveness of physical
activity and exercise on QoL, as well as objectively-measured and patient-reported outcomes in patients with melanoma. The main finding of this review was that physical
activity/exercise did not adversely impact QoL, or objectively-measured (body composition, physical function, and
cardiorespiratory fitness) and patient-reported (fatigue,
treatment-related side-effects, cognitive function, and psychological distress) outcomes in patients with melanoma. In
addition, major methodological and reporting issues are
present within many of the currently available studies, highlighting a lack of quality research examining the relationship between physical activity/exercise and patient
outcomes and current treatment side-effects.
Reductions in QoL are common as a result of treatment
toxicities and are more pronounced in those patients with
regional and metastatic disease.38-41 While this review did
not demonstrate that physical activity and exercise have an
additional effect on QoL, they likely help to maintain QoL
levels in patients with melanoma during or after treatment.
Although the previous studies by Blanchard et al30 and
Carmeli and Bartoletti31 both suggest that in patients with
melanoma confined to the primary site or with regional disease physical activity/exercise is significantly associated
with improved QoL, no significant change in QoL levels
was observed following 8 weeks of exercise in the intervention study of Lacey et al.33 This result may be related to the
lack of exercise control as well as having prescribed vastly
different exercise modalities without supervision. In addition, this study33 did not present further information regarding the desired or achieved intensities undertaken during
the exercise program. In previous studies, for example,
unsupervised exercise programs tend to produce modest
changes when compared to supervised exercise programs
on QoL,42 and this may have attenuated the exercise effects
in patients with melanoma. Furthermore, the poor exerciserelated reporting and lack of supervision also preclude us
from determining if the minimal exercise stimulus to elicit
benefits in QoL was achieved in this group of patients.43 In
this way, despite several studies demonstrating the benefits
of exercise medicine on QoL in different cancer populations,37,42,44,45 including metastatic disease,46 methodologically sound trials with exercise interventions of appropriate
mode and dosage are needed to determine exercise efficacy
on QoL in patients with melanoma.
Fatigue is one of the most prevalent symptoms across
different cancers and treatments,47,48 and although the
cause is multifactorial there is substantial evidence demonstrating the role of exercise medicine in reducing this
symptom across several cancer types.49 In the studies
included in our review, although physically active patients
experienced less fatigue as a result of self-guided exercise
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in the cross-sectional study by Hyatt et al,32 neither of the 2
included intervention trials33,34 produced meaningful
changes in this outcome. This is possibly related to the generally low levels of fatigue presented by the included
patients with melanoma at baseline. The moderation of this
outcome by the baseline levels is such that patients respond
better to the exercise programs if they present with higher
levels of fatigue.49 Furthermore, another reason may be
related to the potential mediators of fatigue in cancer
patients.50,51 Researchers have suggested that both muscle
mass and inflammatory markers play a role in the fatigue
reduction observed in prostate50 and breast cancer patients51
following exercise interventions. However, only one of the
intervention studies included in this review assessed fat mass
and lean mass,33 presenting no substantial change in these
outcomes, while neither measured inflammatory markers.33,34
This may be considered an important outcome for patients
with melanoma given the benefits of resistance training programs on fatigue, muscle mass and metabolic health already
demonstrated in other cancer populations.37,43
In addition to the contribution of body composition to
attenuate cancer-related fatigue; muscle and fat mass are
also associated with physical independence, hospitalization, treatment toxicities, and survival outcomes in cancer
patients.8,52-57 Of the 2 intervention studies included in this
review, neither reported exercise benefits on muscle mass,
fat mass or body weight among patients with melanoma,33,34
which is a concern for this specific patient population, given
the prevalence of sarcopenia. The prevalence of sarcopenia
increases ~15% in patients receiving checkpoint inhibitor
therapy (ipilimumab/PD-1)8 and this represents a major
issue in terms of overall survival as well as treatment tolerance in this group of patients. The maintenance of body
mass and in particular muscle mass, may be important to
patients with melanoma with regional or metastatic disease
who are receiving checkpoint inhibitor therapy given
improved survival outcomes compared to those presenting
with drastic reductions during treatment.58 Therefore, treatment-related reductions in body weight could be harmful in
melanoma patients receiving either targeted therapy or
immune checkpoint inhibitor therapy which contradicts
previous reports concerning prostate or breast cancer,59-61
where a higher body mass negatively impacts treatment and
survival outcomes. Thus, more research is needed to determine the effects of exercise on this specific outcome in
patients with melanoma. Moreover, no meaningful effect
attributed to physical activity/exercise was observed on
cognitive function,34 psychological distress,33 physical
function,34 or even cardiorespiratory fitness33 in the studies
included in our review. This relates to the likely suboptimal
exercise programs implemented with these patients (such as
volume, intensity, and mode of exercise), as such benefits in
psychological distress, physical function, and cardiorespiratory fitness are consistently demonstrated within other
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cancer types.11,18 With regard to cognitive function, there is
evidence of aerobic exercise having a positive effect on
older adults’ cognition, although such effects in patients
with cancer remains unclear.11
Treatment-related side-effects can impact patients with
melanoma receiving a variety of treatment modalities. As
previously mentioned, the addition of checkpoint inhibitor
therapy to standard care has given rise to a range of irAEs,
unlike those seen in more traditional treatments.9 In the
study by Lacey et al,33 immune checkpoint inhibitor treatment-related side-effects and symptoms within the exercise
group were described as both stable and comparable to the
standard care control group. This may be related to participant characteristics; many had previously been treated with
immunotherapy (82%) and were long-term regional and
metastatic melanoma survivors with a low symptom load at
baseline.33 Nevertheless, it appears that over this 8-week
intervention, exercise did not negatively influence participants’ irAEs.
Although systemic treatment with immunotherapy or
targeted therapy is being used increasingly for both regional
and metastatic melanoma, regional surgery for lymph node
clearance (whether sentinel or complete lymph node dissection) is still commonly used. Complete lymph node dissection has been largely abandoned62,63; however,
lymphoedema remains a potential side-effect of lymph
node dissection. Lymphoedema is often treated via a multimodal approach, including massage, compression bandages/stockings, and specific elastic band exercises.64 Both
Carmeli & Bartoletti31 and Hinrichs et al35 utilized this
multimodal approach, reporting significant reductions in
lymphoedema. However, it is important to note that exercise comprised only one part of a comprehensive therapy.
Contrary to earlier suggestions, the International Society of
Lymphology65 describes both vigorous exercise and resistance exercise under controlled conditions (supervised) as
safe for peripheral lymphoedema patients. In breast cancer
patients with secondary lymphoedema, both aerobic and
resistance exercise are safe, while resistance exercise has
been suggested as being more effective at reducing lymphoedema symptoms than usual care.13,66,67 Although comparable lymphoedema symptoms are experienced by patients
with melanoma, similar trials have not been undertaken in
this patient population.
To our knowledge, this is the first systematic review
focusing on the effects of physical activity and exercise in
patients with melanoma. Given the paucity of the published research in this area, a strength of this review is the
broad inclusion criteria that enabled a comprehensive
evaluation of relevant publications in this underdeveloped
field as well as a number of suggestions for future research
in this patient group. However, some limitations are worthy
of comment. The small number of included studies with
various study designs produced significant heterogeneity
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in the present report. For example, the limited evidence
from physical activity/exercise trials in melanoma patient
precludes observing trends in this current data, such as
direction of results indicating benefits derived from physical activity or exercise programs. In addition, restricted
outcome reporting and methodological issues also limited
our conclusions about the efficacy of physical activity/
exercise in patients with melanoma. Therefore, additional
research is required to examine the effects of exercise
medicine in this group of patients. Future well-designed
single group studies with more rigorous exercise interventions and robust reporting are warranted, balancing
patients’ needs and goals given the range of side-effects
experienced by patients with melanoma throughout the
cancer care continuum. Finally, only articles published in
English were included in this review and this may be considered a limitation.
In summary, there is some evidence that physical activity/exercise might present potential benefits in patients with
melanoma, although major methodological and reporting
limitations were present in the included studies. Thus, the
main finding of this systematic review is that physical activity/exercise did not adversely impact the objectively-measured or patient-reported outcomes of patients with
melanoma. This is important to support future research in
this field examining the exercise effects on QoL, fatigue,
body composition, physical function, cardiorespiratory fitness, treatment-related side-effects, cognitive function, and
psychological distress. As a result, future well-designed
studies examining the role of exercise medicine in patients
with melanoma are warranted and may potentially enhance
patient outcomes.
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